RCUS FY 2020 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+420.0% YoY

Gross Profit

$78M100.0% margin

Operating Income

-$124M-159.0% margin

Net Income

-$123M-157.7% margin

EPS (Diluted)

$-2.13

Cash Flow

Operating Cash Flow

$111M

Free Cash Flow

$108M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$772M

Total Liabilities

$270M

Stockholders' Equity

$502M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$15M	+420.0%
Gross Profit	$78M	$15M	+420.0%
Operating Income	-$124M	-$89M	-39.8%
Net Income	-$123M	-$85M	-45.2%